1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Heparin Sodium Injection, Sterile Solution, USP

<table>
<thead>
<tr>
<th>Trade Name:</th>
<th>Heparin Sodium Injection, USP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Intended Use:</td>
<td>Pharmaceutical product used as anticoagulant agent</td>
</tr>
</tbody>
</table>

2. HAZARDS IDENTIFICATION

Appearance: Clear, colorless, to very pale, straw colored

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additonal Hazard Information:
- Short Term: May cause eye irritation (based on components) May produce allergic reactions following skin contact.

Known Clinical Effects: Clinical use of this drug has caused hemorrhage, gastrointestinal bleeding, increased bleeding time. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

EU Classification
- EU Indication of danger: Not classified


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Dalteparin Sodium (Heparin Sodium)</td>
<td>9041-08-1</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>1,000-10,000 units/mL</td>
</tr>
</tbody>
</table>

Dalteparin Sodium (Heparin Sodium)

Registration Number: 01-2119430937-32-0000

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: This material produces toxic fumes of nitrogen and sulfur oxides, carbon dioxide, and carbon monoxide during fires.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

PZ01146
7. HANDLING AND STORAGE

General Handling: Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Dalteparin Sodium (Heparin Sodium)
Pfizer OEL TWA-8 Hr: 200µg/m³

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- Eyes: Wear safety glasses or goggles if eye contact is possible.
- Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution
Color: Colorless to pale straw-color

Molecular Formula: Mixture
Molecular Weight: Mixture

Solubility: Soluble: Water
pH: 5.0-7.5

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

<table>
<thead>
<tr>
<th>Substance</th>
<th>Species</th>
<th>Route</th>
<th>LD 50</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dalteparin Sodium (Heparin Sodium)</td>
<td>Rat</td>
<td>Oral</td>
<td>&gt; 5000 mg/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Oral</td>
<td>&gt; 5000 mg/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Intraperitoneal</td>
<td>&gt; 2500 mg/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Intraperitoneal</td>
<td>2500 mg/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Intravenous</td>
<td>2800 mg/kg</td>
<td></td>
</tr>
</tbody>
</table>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

<table>
<thead>
<tr>
<th>Substance</th>
<th>Study Type</th>
<th>Species</th>
<th>Route</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dalteparin Sodium (Heparin Sodium)</td>
<td>Eye Irritation</td>
<td>Rabbit</td>
<td></td>
<td>Mild</td>
</tr>
</tbody>
</table>

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

<table>
<thead>
<tr>
<th>Substance</th>
<th>Study Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dalteparin Sodium (Heparin Sodium)</td>
<td>Fertility and Embryonic Development</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>10 mg/kg/day</td>
<td>NOAEL</td>
<td>Fertility, Fetotoxicity</td>
</tr>
<tr>
<td></td>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>Intravenous</td>
<td>10,000 mg/kg/day</td>
<td>LOAEL</td>
<td>Fetotoxicity</td>
</tr>
<tr>
<td></td>
<td>Embryo / Fetal Development</td>
<td>Rabbit</td>
<td>Intravenous</td>
<td>2,500 mg/kg/day</td>
<td>LOAEL</td>
<td>Fetotoxicity</td>
</tr>
</tbody>
</table>

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications
WHMIS hazard class:
None required

Water

Inventory - United States TSCA - Sect. 8(b)  Listed
Australia (AICS):  Listed
REACH - Annex IV - Exemptions from the obligations of Register:
EU EINECS/ELINCS List  231-791-2

Dalteparin Sodium (Heparin Sodium)

Inventory - United States TSCA - Sect. 8(b)  Listed
Australia (AICS):  Listed
Standard for the Uniform Scheduling for Drugs and Poisons:  Schedule 4

16. OTHER INFORMATION

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet